NasdaqCM - Nasdaq Real Time Price USD

Galmed Pharmaceuticals Ltd. (GLMD)

1.2400

-0.0100

(-0.80%)

At close: May 9 at 4:00:01 PM EDT

1.2200

-0.02

(-1.61%)

After hours: May 9 at 7:25:06 PM EDT

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 353% surge in interest Protagenic Therapeutics (PTIX), 345% surge in interest Hepion Pharmaceuticals (HEPA), 310% surge in interest Rigel Pharmaceuticals (RIGL), 290% surge in interest Bolt Biotherapeutics (BOLT), 274% surge in interest Palatin Technologies (PTN), 274% surge in interest Krystal Biotech (KRYS), 240% surge in

TipRanks yesterday

KRYS

JAZZ

HEPA
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that the first set of oncology studies has shown that Aramchol enhances the liver / colorectal cancer-approved therapeutic Regorafenib effects in liver and colon cancers in-vitro and in-vivo models.

PR Newswire 5 days ago

GLMD
-0.80%
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological indications announced today that it has signed a binding term-sheet with Entomus s.r.o. for a license agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation that allows absorption of sublingually administrated peptides such as GLP-1 (Semaglutide, Liraglutide etc.).

PR Newswire 13 days ago

GLMD
-0.80%
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company, today announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal (GI) cancers. Under the Sponsored Project Agreement, VCU scientists will study Aramchol in preclinical models of advanced GI malignancies – focusing on colorectal and hepatocellular (liver) cancers – in

PR Newswire 24 days ago

GLMD
-0.80%
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing novel treatments for liver, cardiometabolic, and gastrointestinal oncology indications, today announces the unveiling of novel pharmacodynamic (PD) blood markers for its lead compound, Aramchol, the industry's most clinically advanced SCD1 inhibitor. These newly identified biomarkers shed fresh light on Aramchol's potential far beyond its role in NASH (MASH)

PR Newswire 26 days ago

GLMD
-0.80%
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine.

PR Newswire last month

GLMD
-0.80%
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the 'SEC').

PR Newswire last month

GLMD
-0.80%
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic diseases and GI oncological indications, today announced the grant of a new patent related to its lead compound, Aramchol. The patent covers the use of a combination therapy of Aramchol and Resmetirom (MGL-3196, Rezdiffra) for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH)

PR Newswire last month

GLMD
-0.80%
Galmed Pharmaceuticals: Q3 Earnings Snapshot

RAMAT GAN, Israel (AP) — Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported a loss of $1.9 million in its third quarter. The Ramat Gan, Israel-based company said it had a loss of $2.31 per share. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.

Associated Press Finance 5 months ago

GLMD
-0.80%
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced today that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients with NASH and fibrosis (ARMOR) have been published in Hepatology.

PR Newswire 7 months ago

GLMD
-0.80%
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for fibroinflammatory indications announced today that based on the recently published results from the Open-Label part of its Phase 3 NASH study, new scientific publications on the role of SCD1 as a critical metabolic signaling hub as well as an extended cash runway, it plans to broaden its drug development activities.

PR Newswire 7 months ago

GLMD
-0.80%

Performance Overview

Return	GLMD	S&P 500 (^GSPC)
YTD	-61.13%	-3.77%
1-Year	-75.10%	+8.55%
3-Year	-85.02%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Galmed Pharmaceuticals Ltd. (GLMD)

Biotech Alert: Searches spiking for these stocks today

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy

Galmed Pharmaceuticals: Q3 Earnings Snapshot

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Performance Overview